Rute Salvador

Rute Salvador


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in European Urology Supplements
Verified
Journal Article
Closed access
FMFelip M. Musquera
Felip M. Musquera
IRI. Revuelta
I. Revuelta
LPL. Peri
L. Peri
FDFritz Diekmann
Fritz Diekmann
ASA. Sanchez-Escudero
A. Sanchez-Escudero
FOF. Oppenheimer
F. Oppenheimer

16 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PRPereira R
Pereira R
SISimões-Gomes I
Simões-Gomes I
MCMaria Guadalupe Cabral
Maria Guadalupe Cabral
JAJacinto A
Jacinto A
RSRute Salvador
Rute Salvador
Dense extracellular matrix deposition, stromal activation and impaired perfusion can create tumour niches that favour lactate accumulation. Lysine lactylation (Kla) provides a molecular link between lactate metabolism, gene expression and protein function, with potential implications for tumour progression and treatment response. Here, we review histone and non-histone lactylation in desmoplastic and stroma-rich tumour contexts, encompassing pancreatic ductal adenocarcinoma and cholangiocarcinoma alongside selected settings in gastric, colorectal, triple-negative breast and hepatocellular cancers. This framework recognises that stromal features vary within and between these malignancies. We synthesise evidence linking lactylation to cancer stemness, fibroblast activation, stromal remodelling and immune suppression, and examine how these processes contribute to therapeutic resistance. Recurrent mechanisms include metabolic adaptation, enhanced DNA repair, suppression of cell death and impaired antitumour immunity. However, lactylation effects depend on the modified protein, lysine residue and cellular context, and are not uniformly tumour-promoting. We critically assess limitations in chemical discrimination, antibody specificity and causal inference, particularly the difficulty of distinguishing Kla-dependent mechanisms from other effects of lactate metabolism. We also discuss therapeutic strategies targeting lactate availability, lactylation enzymes and individual substrates. Most evidence remains preclinical, highlighting the need for quantitative, site-specific and spatially resolved analyses, functional validation and prospective clinical studies. Establishing which lactylation events directly influence tumour behaviour and treatment response will be essential for translating these findings into selective therapies and clinically informative biomarkers.

9 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TMTelma Martins
Telma Martins
RSRute Salvador
Rute Salvador
BCBruna Filipa Correia
Bruna Filipa Correia
DGDaniela Grosa
Daniela Grosa
MVMarina Vitorino
Marina Vitorino
MCMaria Guadalupe Cabral
Maria Guadalupe Cabral
Neutrophils, once viewed as short-lived and functionally uniform antimicrobial cells, are now recognized as highly plastic immune regulators with context-dependent roles in cancer. Among circulating neutrophil subsets, low-density neutrophils (LDNs) have emerged as a clinically relevant population in oncology due to their distinct phenotypic, potent immunosuppressive activity, and strong association with disease progression. LDNs are rare in healthy individuals but markedly expanded in patients with solid tumors.LDNs display enhanced activation, increased expression of immunoregulatory molecules such as programmed death‑ligand 1, elevated reactive oxygen species production, and a heightened propensity for neutrophil extracellular trap formation, collectively impairing cytotoxic T cell function and promoting tumor immune evasion.Although LDNs have been described across multiple malignancies, their biological and clinical relevance has been most characterized in breast and lung cancers. This review synthesizes current knowledge on neutrophil biology, emphasizing the clinical and mechanistic features of LDNs, with a focus on these two tumor types.In breast cancer, increased LDNs abundance correlates with metastatic disease, poor response to neoadjuvant chemotherapy, immunosuppression, accelerated progression, and reduced survival. In lung cancer, elevated LDNs frequencies similarly associate with advanced disease stage, unfavorable clinical outcomes, and distinct surface marker profiles distinguishing them from high-density neutrophils.Mechanistic studies indicate that tumor-derived cytokines and chronic inflammation drive LDNs expansion, functional reprogramming, and tissue trafficking, linking systemic neutrophil dysregulation to tumor progression.Finally, we highlight emerging biomarkers, unresolved challenges, and therapeutic strategies targeting neutrophil plasticity and LDN-mediated immunosuppression, underscoring their potential as actionable components in precision oncology.

26 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ATAna Tomás
Ana Tomás
JMJosé Maximino
José Maximino
HNHugo Nunes
Hugo Nunes
RSRute Salvador
Rute Salvador
RLRafael Luís
Rafael Luís
MPMarta Pojo
Marta Pojo
Background: Cutaneous melanoma (CM) is an aggressive skin cancer with rising incidence, representing a growing public health concern. Despite the remarkable success of immune-checkpoint inhibitors (ICIs) in the management of advanced disease, mortality remains high due to therapy resistance. Identifying reliable prognostic and predictive biomarkers is therefore essential to improve patient stratification, optimize treatment selection, and minimize unnecessary toxicity. Methods: We comprehensively profiled the circulating immune landscape of 54 treatment-naïve CM patients by integrating flow cytometry immunophenotyping with clinicopathological data, and performed tumor gene expression analysis in a subset of 26 patients. Results: Elevated HLA-DR and CD69 expression on circulating CD4 + T cells, together with reduced circulating CD8 + T cell frequency, emerged as candidate prognostic biomarkers associated with improved survival. Prognostic models combining these immune variables with clinical covariates accurately stratified patients by overall survival (89.5% sensitivity, 72.7% specificity; AUC = 0.872, p < 0.0001) and progression/recurrence risk (75% sensitivity and 71.4% specificity; AUC = 0.763, p = 0.001). In a subset of 43 patients subsequently treated with ICIs, elevated baseline HLA-DR and CD69 expression on circulating CD4 + T cells was also associated with therapeutic benefit. A predictive model integrating these markers with clinical covariates achieved good discriminatory performance (65.2% sensitivity, 88.9% specificity; AUC = 0.775, p = 0.0027). Tumor gene expression profiling supported the role of IFN-γ-related signatures, previously linked to ICI response, as complementary prognostic and predictive tools. Conclusion: These findings highlight systemic CD4 + T cell activation status as a promising, easily measurable biomarker in CM, laying the foundation for future strategies to refine patient stratification and guiding immunotherapy decisions.